Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2018 09:45 ET | Source: Rich Pharmaceuticals

Rich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma

BEVERLY HILLS, CA , March 14, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology,...